[1]IDF Diabetes Atlas, 10th edn. International Diabetes Federation, 2021 [2]Data source: IQVIA PDS database, 2022Q2~2023Q1, Endo, Total (n=14,235), New patient (n=2,278) [3]Ji LN, et al. BMC Public Health. 2013; 13: 602.[4]Ji L, Hu D, Pan C, Weng J, Huo Y, Ma C, Mu Y, Hao C, Ji Q, Ran X, Su B, Zhuo H, Fox KA, Weber M, Zhang D; CCMR Advisory Board; CCMR-3B STUDY Investigators. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med. 2013 Oct;126(10):925.e11-22. doi: 10.1016/j.amjmed.2013.02.035. Epub 2013 Jun 27. PMID: 23810406.[5]Cosentino F, et al. Eur Heart J. 2020 Jan 7;41(2):255-323 [6]Aroda VR et al. Diabetes Care 2019;42:1724–32 [7]Rodbard HW et al. Diabetes Care. 2019;42(12):2272–2281 [8]Rosenstock J et al. JAMA 2019;321:1466–80 [9]Pratley R et al. Lancet 2019;394:39–50 [10]Mosenzon O et al. Lancet Diabetes Endocrinol 2019;7:515–27 [11]Husain M et al. N Engl J Med 2019. 381:841–51 [12]Pieber TR et al. Lancet Diabetes Endocrinol 2019;7:528–39 [13]Zinman B et al. Diabetes Care. 2019;42(12):2262–2271 [14]Yamada et al. Lancet Diabetes Endocrinol 2020;8:377–91 [15]Yabe et al. Lancet Diabetes Endocrinol 2020;8:392–6. [16]PIONEER 11:Weiqing Wang, et al. 2022 IDF. eposter presentation [17]PIONEER 12:Linong Ji, et al. 2022 IDF. eposter presentation [18]PIONEER 11 Data on file. [19]Buckley ST et al. Sci Transl Med 2018;10:eaar7047. * 截至2024年1月 # 优质达标:HbA1c<7%、无严重或确证性低血糖且无体重增加 “此文仅用于向医疗卫生专业人士提供科学信息,不代表平台立场”